Transcriptomics-Guided Design of Synthetic Promoters for a Mammalian System.

Despite recent advances in improving titers for therapeutic proteins such as antibodies to the 10 g/L scale, these high yields can only be achieved in select mammalian hosts. Regardless of the host or product, strong promoters are required to obtain high levels of transgene expression. However, the promoters employed to drive this expression are rather limited in variety and are usually either viral-derived or screened empirically during vector design. To begin to move away from viral parts, we employed a more systematic approach to identify and design new synthetic promoters using endogenous elements. To do so, we established a workflow to design these elements by (1) analyzing the transcriptomics profile of a specific cell line under a desired, representative cell culture condition, (2) identifying key genetic motifs using bioinformatics that can be used to rationally construct synthetic promoters, (3) building synthetic promoters using conventional DNA synthesis and molecular biology techniques, and (4) evaluating the performance of these synthetic promoters using model proteins. The resulting promoters perform comparably to the hCMV IE promoter variants tested, but with endogenous components. During this design-build-test cycle we also investigated the underlying design rules for transcription factor binding site arrangement in synthetic promoters. Overall, this approach of using an "omics-guided" workflow for designing synthetic promoters facilitates the construction of high expression vectors for immediate use in current production hosts.

[1]  Feng Li,et al.  Cell culture processes for monoclonal antibody production , 2010, mAbs.

[2]  M. Fussenegger,et al.  An engineered epigenetic transgene switch in mammalian cells , 2004, Nature Biotechnology.

[3]  S. Levy,et al.  Predicting transcription factor synergism. , 2002, Nucleic acids research.

[4]  J. Black,et al.  Sp1 and krüppel‐like factor family of transcription factors in cell growth regulation and cancer , 2001, Journal of cellular physiology.

[5]  D. Covas,et al.  Human cells: new platform for recombinant therapeutic protein production. , 2012, Protein expression and purification.

[6]  Chuong B Do,et al.  What is the expectation maximization algorithm? , 2008, Nature Biotechnology.

[7]  I. Pastan,et al.  The Rous sarcoma virus long terminal repeat is a strong promoter when introduced into a variety of eukaryotic cells by DNA-mediated transfection. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[8]  P. Angel,et al.  AP-1 subunits: quarrel and harmony among siblings , 2004, Journal of Cell Science.

[9]  R. Jackson,et al.  Defective point mutants of the encephalomyocarditis virus internal ribosome entry site can be complemented in trans. , 1995, Virology.

[10]  Kathleen A. Curran,et al.  Design of synthetic yeast promoters via tuning of nucleosome architecture , 2014, Nature Communications.

[11]  Alexander E. Kel,et al.  TRANSFAC® and its module TRANSCompel®: transcriptional gene regulation in eukaryotes , 2005, Nucleic Acids Res..

[12]  Hal S. Alper,et al.  The development and characterization of synthetic minimal yeast promoters , 2015, Nature Communications.

[13]  G. Rubanyi,et al.  Transcriptional silencing is associated with extensive methylation of the CMV promoter following adenoviral gene delivery to muscle , 2004, The journal of gene medicine.

[14]  C. Glass,et al.  Metabolic engineering of Chinese hamster ovary cells: towards a bioengineered heparin. , 2012, Metabolic engineering.

[15]  Nathan C. Sheffield,et al.  The accessible chromatin landscape of the human genome , 2012, Nature.

[16]  Modulating ectopic gene expression levels by using retroviral vectors equipped with synthetic promoters , 2011, Systems and Synthetic Biology.

[17]  Adam J Brown,et al.  Synthetic promoters for CHO cell engineering , 2014, Biotechnology and bioengineering.

[18]  Bruce T. Lahn,et al.  Systematic Comparison of Constitutive Promoters and the Doxycycline-Inducible Promoter , 2010, PloS one.

[19]  W. Schaffner,et al.  The SV40 enhancer can be dissected into multiple segments, each with a different cell type specificity. , 1987, Genes & development.

[20]  M. Griffiths,et al.  CpG-island fragments from the HNRPA2B1/CBX3 genomic locus reduce silencing and enhance transgene expression from the hCMV promoter/enhancer in mammalian cells , 2005, BMC biotechnology.

[21]  D. S. Allison,et al.  High‐Level Expression of Proteins in Mammalian Cells Using Transcription Regulatory Sequences from the Chinese Hamster EF‐1α Gene , 2004, Biotechnology progress.

[22]  Susanna Zucca,et al.  Bottom-Up Engineering of Biological Systems through Standard Bricks: A Modularity Study on Basic Parts and Devices , 2012, PloS one.

[23]  W. Schaffner,et al.  Simian Virus 40 Strains with Novel Properties Generated by Replacing the Viral Enhancer with Synthetic Oligonucleotides , 2012, Journal of Virology.

[24]  S. J. Wilkinson,et al.  Model‐directed engineering of “difficult‐to‐express” monoclonal antibody production by Chinese hamster ovary cells , 2014, Biotechnology and bioengineering.

[25]  Hal S. Alper,et al.  Emerging synthetic biology tools for engineering mammalian cell systems and expediting cell line development , 2012 .

[26]  Michael Boshart,et al.  A very strong enhancer is located upstream of an immediate early gene of human cytomegalovirus , 1985, Cell.

[27]  Huong Le,et al.  Dynamic gene expression for metabolic engineering of mammalian cells in culture. , 2013, Metabolic engineering.

[28]  Yuansheng Yang,et al.  Identifying and engineering promoters for high level and sustainable therapeutic recombinant protein production in cultured mammalian cells , 2014, Biotechnology Letters.

[29]  P. R. Jensen,et al.  Generation of a synthetic mammalian promoter library by modification of sequences spacing transcription factor binding sites. , 2002, Gene.

[30]  Michael Q. Zhang,et al.  Genome-wide map of regulatory interactions in the human genome , 2014, Genome research.

[31]  Joseph K. Cheng,et al.  The genome editing toolbox: a spectrum of approaches for targeted modification. , 2014, Current opinion in biotechnology.

[32]  Mariati,et al.  Insertion of core CpG island element into human CMV promoter for enhancing recombinant protein expression stability in CHO cells , 2014, Biotechnology progress.

[33]  Brian Kelley,et al.  Industrialization of mAb production technology: The bioprocessing industry at a crossroads , 2009, mAbs.

[34]  J E Bailey,et al.  Autoregulated Multicistronic Expression Vectors Provide One‐Step Cloning of Regulated Product Gene Expression in Mammalian Cells , 1997, Biotechnology progress.

[35]  Saurabh Aggarwal,et al.  What's fueling the biotech engine—2012 to 2013 , 2014, Nature Biotechnology.

[36]  S. Elledge,et al.  Synthetic design of strong promoters , 2010, Proceedings of the National Academy of Sciences.

[37]  Martha L. Bulyk,et al.  UniPROBE, update 2015: new tools and content for the online database of protein-binding microarray data on protein–DNA interactions , 2014, Nucleic Acids Res..

[38]  Swneke D. Bailey,et al.  ZNF143 provides sequence specificity to secure chromatin interactions at gene promoters , 2015, Nature Communications.

[39]  J. Stelling,et al.  A tunable synthetic mammalian oscillator , 2009, Nature.

[40]  N. Mermod,et al.  CHO cell engineering to prevent polypeptide aggregation and improve therapeutic protein secretion. , 2014, Metabolic engineering.

[41]  Vladimir B. Bajic,et al.  HOCOMOCO: a comprehensive collection of human transcription factor binding sites models , 2012, Nucleic Acids Res..

[42]  G. Church,et al.  Large-scale de novo DNA synthesis: technologies and applications , 2014, Nature Methods.

[43]  Xiaohui Xie,et al.  MotifMap: integrative genome-wide maps of regulatory motif sites for model species , 2011, BMC Bioinformatics.

[44]  Z. Yakhini,et al.  Inferring gene regulatory logic from high-throughput measurements of thousands of systematically designed promoters , 2012, Nature Biotechnology.

[45]  Michael C. Jewett,et al.  Biology by Design: From Top to Bottom and Back , 2010, Journal of biomedicine & biotechnology.

[46]  P. Becker,et al.  CMV promoter mutants with a reduced propensity to productivity loss in CHO cells , 2015, Scientific Reports.

[47]  David J. Arenillas,et al.  JASPAR 2014: an extensively expanded and updated open-access database of transcription factor binding profiles , 2013, Nucleic Acids Res..

[48]  Minsoo Kim,et al.  A mechanistic understanding of production instability in CHO cell lines expressing recombinant monoclonal antibodies , 2011, Biotechnology and bioengineering.

[49]  Daniel G. Anderson,et al.  Non-viral vectors for gene-based therapy , 2014, Nature Reviews Genetics.

[50]  Steven C Almo,et al.  Recent advances in mammalian protein production , 2014, FEBS letters.

[51]  Debashis Ghosh,et al.  Mixture modelling of gene expression data from microarray experiments , 2002, Bioinform..